Ferring Pharmaceuticals: Ferring Pharmaceuticals: Ferring Announces Initial Data from Phase 3 Trial in Japanese Patients Demonstrating 75% Complete Response Rate at 3 Months with (nadofaragene firadenovec) in BCG-unresponsive NMIBC Patients1
First results from a Phase 3 trial conducted across 25 centers in Japan were presented at the Annual Meeting of the Japanese Urological Association, highlighting Ferring's ongoing commitment to es...
Read full article »
Ferring Pharmaceuticals is focused on the development and marketing of drugs for the treatment of various diseases.
Read more